Clover (三叶草生物) Pre-IPO: COVID-19 Wildcard
We look at Clover's key products, including SCB-2019 (COVID-19 vaccine), SCB-313 (for intracavitary malignancies), and SCB-808 (biosimilar of...
320 Views
ECM Weekly (17th October 2021) - SG Lottery, GQG, Judo Bank, Vulcan Steel, Biocytogen, Kakao Pay
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
379 Views
Clover Biopharmaceutical IPO: Covid-19 Vaccine Candidate Shows Strong Potential
Clover’s most advanced drug asset is a Covid-19 vaccine candidate, SCB-2019 and the company expects to receive conditional approval in the near...
347 Views
Pre-IPO Sirnaomics Ltd. - Cautious Optimism Is Still Recommended
This article mainly analyzed Sirnaomics in terms of the industry characteristics, the delivery platforms, the pipeline and the concerns of the...
270 Views
Pre-IPO Jiangsu Recbio Technology - There Are Many Uncertainties
This article mainly analyzed Recbio Technology in terms of the vaccine industry characteristics, core product candidates (HPV vaccines, COVID-19...
243 Views